Vida Ventures
Venture Capital
Active
Boston, United States
53
98M
35
7.57
12
0.34
11
- Stages of investment
- Areas of investment
Summary
In 2017 was created Vida Ventures, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Boston.
This organization was formed by Arjun Goyal, Len Potter, Stefan Vitorovic. Besides them, we counted 4 critical employees of this fund in our database.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vida Ventures, startups are often financed by SV Health Investors, Skyline Ventures, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Nextech Invest, OrbiMed, The Column Group. In the next rounds fund is usually obtained by Perceptive Advisors, Nextech Invest, venBio Select Advisor.
Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, Pionyr Immunotherapeutics, Kronos Bio. The fund has no exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year. The common things for fund are deals in the range of more than 100 millions dollars. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2018. This Vida Ventures works on 4 percentage points more the average amount of lead investments comparing to the other organizations.
Investor highlights
- Industry focus
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 825000000
- Fund raised date
- 2021-06-24
Analytics
- Total investments
- 53
- Lead investments
- 12
- Exits
- 11
- Rounds per year
- 7.57
- Follow on index
- 0.34
- Investments by industry
- Biotechnology (46)
- Health Care (24)
- Therapeutics (20)
- Pharmaceutical (15)
- Medical (14) Show 17 more
- Investments by region
-
- United States (49)
- China (1)
- Netherlands (1)
- France (1)
- India (1)
- Peak activity year
- 2020
- Number of Unicorns
- 2
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 113M
- Group Appearance index
- 0.98
- Avg. company exit year
- 9
- Avg. multiplicator
- 3.26
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Aktis Oncology | 25 Aug 2022 | Biotechnology, Life Science | Early Stage Venture | 84M | United States, Massachusetts, Boston |
InduPro | 13 Jun 2024 | Early Stage Venture | 85M | United States, Washington, Seattle |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.